China Orders Ban On Painkiller Vaccine Of Local Drug Maker
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities ordered a halt to the use of a pain-killing injection made by Zhejian Tianrui Pharmaceutical. The Ministry of Health said 13 patients in Zhongshan City had serious adverse reactions after receiving injections of the Xiangdan vaccine to activate blood circulation and kill pain. Follow-up tests on the vaccine showed the pyrogen agent in the suspect batch was below standards. The ministry ordered all hospitals and medical institutes that received vaccines of one batch number to stop using the injection immediately. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.